Introduction
Colorectal cancer (CRC) is one of the most common types of fatal malignant tumors worldwide [
1]. Recently published data show that CRC is the third leading cause of cancer mortality, accounting for 9% of all cancer-related deaths in the USA [
2]. More worryingly, the age at onset is becoming younger age. In individuals less than 50 years old, the incidence and death rate have increased by approximately 2% and 1.3% annually in recent years, respectively [
3]. As colitis is one of the predisposing risk factors in CRC, CAC accounts for approximately 5% of CRC cases [
4].
Prolonged inflammation is one of the characteristics of tumors, and many cancers develop in response to chronic inflammation or display the hallmarks of prolonged inflammation throughout their progression [
5‐
7]. CAC is one of the best examples of tumors that are tightly related to chronic inflammation, which is present in the earliest stage of tumor onset [
7]. CAC develops in patients with inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), two clinical phenotypes with risks that are estimated to increase by 0.5–1% per year after 8 to 10 years of IBD [
8]. Strikingly, CAC can be delayed or even prevented by treatment with anti-inflammatory drugs, suggesting that inflammatory processes are involved in tumor onset [
7].
Pyroptosis was initially considered to be caspase-1-mediated necrosis, mainly in response to bacterial invasion [
9]. Recent studies have shown that gasdermin D (GSDMD) and GSDME are cleaved by active caspase-1/4/5/11 and caspase-3, respectively, via the middle linker, releasing their gasdermin-N fragments to induce pyroptosis by perforating the cell membrane [
10‐
12]. This pore-forming activity causes cytoplasmic swelling and releases intracellular contents, such as immunogenic damage-associated molecular patterns (DAMPs) [
13,
14]. Therefore, pyroptosis has been redefined as gasdermin-mediated proinflammatory cell death [
10,
12]. Because pyroptosis promotes inflammation, it is likely to play an important role in colitis and CAC development. However, it is still not clear whether pyroptosis participates in colitis and CAC development.
DAMPs consist of structurally diverse nonpathogen-derived molecules, and they share some of the following characteristics: (1) they can bind to and activate cell surface or intracellular pattern recognition receptors (PRRs) [
15]; (2) they can be not only actively secreted from stressed cells but can also passively released when the plasma membrane is disrupted following certain forms of cell death, such as necrosis, necroptosis, and pyroptosis [
16,
17]; and (3) they may switch from a physiological to a proinflammatory function after being released into the extracellular milieu [
17]. Various DAMPs have been recognized, including HMGB1, lactoferrin (LTF), S100 proteins A8 and A9 (S100A8/9), IL1a, and IL33 [
17]. However, the functional relevance and the effects of these DAMPs on CAC are not entirely clear.
The purpose of this study was to determine the role of gasdermin-mediated pyroptosis in colitis and CAC development. For this purpose, we explored the significance of gasdermin-mediated pyroptosis in experimentally induced colitis and CAC and elucidated its important role in colitis and CAC pathogenesis.
Methods
Antibodies and reagents
Anti-GSDME (ab230482) and anti-PCNA antibodies (ab92552) were obtained from Abcam. Anti-ERK (4695), anti-p-ERK (4370), anti-JNK (9252), anti-p-JNK (4668), anti-P38 (8690), and anti-p-P38 (4511) were obtained from Cell Signaling Technology. The neutralizing HMGB1 antibody (ab79823) was purchased from Abcam. Dextran sulfate sodium (DSS) was obtained from MP Biomedicals. AOM (A5486) was purchased from Sigma-Aldrich. Recombinant mouse TNF-α (315-01A) was obtained from PeproTech. Cycloheximide (CHX, C7698), a eukaryote protein synthesis inhibitor, was purchased from Sigma-Aldrich. Recombinant mouse HMGB1 protein (ab181949) was obtained from Abcam. U0126, an ERK1/2 inhibitor, was obtained from InvivoGen. Mouse HMGB1 (E0399m) and IL1a (E0071m) ELISA kits were obtained from EIAab Science Inc, Wuhan. Mouse S100A8 (YXL20093) and S100A9 (YXL20095) ELISA kits were obtained from Yuannuo Science Inc, Chengdu. Mouse LTF (MM-0310M2) and IL33 (MM-0935M2) ELISA kits were obtained from Meimian Science Inc, Guangzhou. Cell counting Kit-8 (CCK8) was obtained from Dojindo Laboratories, Japan.
Human samples
Endoscopic colonic mucosal biopsy samples were collected from IBD patients and healthy donors at the Nanfang Hospital Gastroenterology Unit. All diagnoses and clinical disease activity assessments were based on a standard combination of clinical, endoscopic and histological assessment and radiologic criteria. All samples were collected from consenting individuals according to the protocols approved by the Ethics Committee of Nanfang Hospital of Southern Medical University. Demographic characteristics are shown in Additional file
1: Table S1.
DSS-induced colitis in mice
Gsdme−/− mice (C57BL/6 strain) were kindly provided by Professor Feng Shao (National Institute of Biological Sciences, Beijing, China).
Gsdme−/− mice and WT mice were bred and maintained in a specific pathogen-free facility, and all animal study protocols were approved by the Institutional Animal Care and Use Committee of Southern Medical University. The
Gsdme−/− and WT mice were littermates and cohoused throughout the experiments. The DSS-induced colitis model was established using a method adapted from a published procedure [
18]. Briefly, 8- to 10-week-old male
Gsdme−/− mice and WT littermate controls were administered 2% DSS dissolved in drinking water. The colon tissues of DSS-challenged mice were embedded in paraffin and stained with H&E. Disease activity index scores and inflammation-associated histopathological assessments were performed according to Nature protocols [
18]. Intestinal pathology scores were assessed by two pathologists in a double-blind manner.
AOM/DSS-induced CAC in mice
CAC was induced with AOM/DSS in mice as described elsewhere [
19]. Briefly, 8- to 10-week-old male
Gsdme−/− mice and WT littermate controls were intraperitoneally injected with AOM (12 mg/kg). Seven days later, the mice were administered 2% DSS dissolved in drinking water for 7 consecutive days, followed by 14 days of regular drinking water for recovery. This same cycle was repeated twice, subsequently followed by regular drinking water until day 84, when these mice were killed. In the antibody-treated groups, neutralizing HMGB1 antibody was intraperitoneally injected at a dose of 200 µg/mouse on days 1, 3, and 5 during DSS treatment. The colons were collected and cut open longitudinally to measure the tumor numbers and sizes.
Immunohistochemistry (IHC)
IHC was conducted to evaluate the expression levels of GSDME in paraffin-embedded tissues using a specific anti-GSDME antibody. The immunoreactive score (IRS) of each sample was obtained by multiplying the score for the percentage of positive cells (0: no positive cells; 1: < 10% positive cells; 2: 10–50% positive cells; 3: 51–80% positive cells; and 4: > 80% positive cells) and the score for the staining intensity (0: no color reaction; 1: mild reaction; 2: moderate reaction; and 3: intense reaction). All sample IRSs were determined by two independent pathologists who were blinded to both the origin of the samples and the patient outcomes.
Isolation of intestinal epithelial cells
Biopsy samples were processed immediately, and IECs were purified using enzymatic digestion as previously described [
20]. Briefly, colonic tissues from the WT and KO mice were repeatedly washed in HBSS containing 1 mM DTT and 1% penicillin/streptomycin (Sigma-Aldrich). Then, IECs were isolated by incubation in HBSS (Invitrogen/GIBCO) containing 3 mM EDTA (Sigma-Aldrich). After enzymatic digestion, a 40% Percoll Plus solution (GE Healthcare) was used to remove the mononuclear cells, red blood cells, and dead cells.
Real-time PCR
Quantitative real-time PCR (qRT-PCR) was performed as previously described [
21]. The mRNA levels of target genes were normalized to that of GAPDH. The primers used are shown in Additional file
1: Table S2.
Cell culture
The mouse colon cancer cell line CT26 was obtained from Guangdong Provincial Key Laboratory of Gastroenterology, Southern Medical University. CT26 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (Gibco) in 5% CO2 at 37 °C.
CCK8 assay
Cell growth was assessed using the CCK8 assay. Briefly, CT26 cells (1 × 103 cells/well) were seeded in 96-well plates. The next day, the cells were treated with 1 µg/ml recombinant mouse HMGB1 protein. After 48 h, 10 µl of CCK8 solution was added to each well and incubated for 1 h before the absorbance was measured at 450 nm.
Western blotting
Western blot analysis was performed as previously described [
22]. GAPDH was used as an endogenous control. Anti-GSDME, anti-p-p38, total p38, p-JNK, total JNK, p-ERK1/2, total ERK1/2, and anti-PCNA antibodies were diluted 1:1000. Anti-GAPDH was diluted 1:2000. Secondary antibodies were diluted 1:4000. ImageJ software was used to quantify and analyze the density of the protein bands.
ELISA
For ELISA analysis, IECs from Gsdme−/− mice and WT littermate controls that were treated with DSS for 7 days were isolated using isolation buffer (5 mM EDTA and 1 mM DTT) and then washed with PBS containing penicillin (100 U/ml) and streptomycin (100 mg/ml) 3 times. Finally, the cells were plated in dishes with DMEM containing 10% FBS for 12 h, and the cell medium was used for ELISA analysis. In our in vitro experiment, isolated IECs from Gsdme−/− mice and WT littermate controls were treated with TNF-α (50 ng/ml) plus CHX (20 µg/ml) for 12 h, and then, the culture supernatant was collected for ELISA analysis.
Statistical analysis
Unless otherwise indicated, statistical analyses were performed using GraphPad Prism software. Except as otherwise indicated, all experimental data are presented as the mean ± SEM, and statistical significance was determined using a two-tailed Student’s t test. P values < 0.05 were considered significant.
Discussion
The most serious complication of IBD is CAC, and one of the hallmarks of CAC is chronic inflammation [
7]. Although inflammation has been identified as a tumor-promoting mechanism in CAC induction [
7], the precise details of this mechanism are still unclear. This study was focused on the precise mechanism by which GSDME-mediated pyroptosis participates in the development of experimentally induced CAC in mice. Our results show that GSDME-mediated pyroptosis and the subsequent release of HMGB1 are associated with CAC tumorigenesis. Mechanistically, our results show that HMGB1 induces CAC tumorigenesis and PCNA expression through the ERK1/2 signaling pathway. PCNA is a chief proliferation marker that reflects the level of cell proliferation [
32,
33]. Our finding is consistent with a previous report showing that blocking the RAGE-HMGB1 axis suppresses the growth and metastases of C6 glioma cells by inhibiting activation of the MAPK pathway [
29].
DAMPs, which are damaged tissue-derived proinflammatory mediators such as HMGB1, S100 proteins, and IL1α, may trigger chronic inflammation and thus promote the development of chronic inflammation-related tumors [
34]. Recent studies have revealed that the plasma membranes of pyroptotic cells rupture and release DAMPs [
16,
35]. In this study, we found that genetic deletion of GSDME, an important executor protein of pyroptosis, could effectively decrease HMGB1 expression and release from colonic tissues in a DSS-induced colitis model. Furthermore, by using anti-HMGB1 therapy in the CAC model, we further determined the role of HMGB1 in promoting CAC tumorigenesis. Our findings suggest that HMGB1 might serve as a novel and attractive therapeutic target for future clinical treatment of CAC.
Interestingly, our data showed that GSDME-deficient mice had a better prognosis than WT mice treated with the neutralizing anti-HMGB1 antibody but had a nonsignificant difference from GSDME-deficient mice treated with neutralizing anti-HMGB1 antibody. These results suggest that GSDME is more important than HMGB1 in CAC tumorigenesis. The limited effect of anti-HMGB1 in this study may have been due to an insufficient dose or frequency. Another possibility is that other DAMPs released from GSDME-mediated pyroptotic cells might also contribute to CAC tumorigenesis.
Notably, a recent study using an AOM-induced CRC model showed that there were no major differences between
Gsdme−/− and WT mice regarding the number of mice bearing microscopic proliferative lesions nor the number of proliferative lesions per mouse [
36]. However, there was a trend toward more affected mice and proliferative lesions in WT mice than in
Gsdme−/− mice [
36]. To investigate why this finding was different from ours, we hypothesize that the discrepancy could be due to the use of different chemically induced colorectal cancer models and different WT controls. In our study, we used an AOM/DSS-induced CAC model and WT littermate controls, while the other group used an AOM-induced CRC model and WT nonlittermate controls. However, whether this is indeed the case remains to be further studied.
Conclusions
In summary, we show that GSDME-mediated pyroptosis contributes to the development of CAC by releasing intracellular HMGB1, which induces tumor cell proliferation and PCNA expression through the ERK1/2 pathway.
Our findings highlight the emerging role of GSDME-mediated HMGB1 secretion in promoting CAC tumorigenesis and provide new insights for the future development of CAC therapeutic strategies by inhibiting GSDME-mediated pyroptosis or using a neutralizing anti-HMGB1 antibody. Future studies are needed to investigate (1) the inflammatory immune response triggered by HMGB1 and its effect on the CAC environment; (2) other DAMPs besides HMGB1 that contribute to CAC development; and (3) the implications for the involvement of other forms of cell death, such as necroptosis and ferroptosis, in CAC tumorigenesis.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.